Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dabigatran
Drug ID BADD_D00563
Description Dabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code B01AE07
DrugBank ID DB14726
KEGG ID D09707
MeSH ID D000069604
PubChem ID 216210
TTD Drug ID D0M7JT
NDC Product Code 51869-0030
UNII I0VM4M70GC
Synonyms Dabigatran | N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine | BIBR 1048 | Pradaxa | Dabigatran Etexilate | Etexilate, Dabigatran | Dabigatran Etexilate Mesylate | Etexilate Mesylate, Dabigatran | Mesylate, Dabigatran Etexilate
Chemical Information
Molecular Formula C25H25N7O3
CAS Registry Number 211914-51-1
SMILES CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Venous thrombosis24.01.01.0080.001835%-
Vitreous haemorrhage06.10.03.001; 24.07.05.0050.001223%
Volvulus07.13.01.0120.001223%-
Pneumoperitoneum07.07.01.0080.000612%-
Hydrothorax22.05.02.0040.000245%-
Intestinal polyp07.20.01.009; 16.05.01.0020.000489%-
Intracardiac thrombus02.11.01.017; 24.01.05.0030.009003%-
Coronary artery dissection02.02.01.004; 12.02.01.035; 24.02.02.0010.000245%-
Ischaemic cardiomyopathy02.04.01.004; 24.04.04.0190.000489%-
Brain oedema12.01.10.010; 17.07.02.0030.003915%
Carotid artery occlusion17.08.01.012; 24.04.06.0080.002447%-
Spinal cord haemorrhage12.01.13.003; 17.08.01.030; 24.07.04.0100.000612%-
Brain death08.04.01.004; 17.02.03.0030.001101%-
Oesophagitis ulcerative07.04.05.0030.000612%-
Sudden cardiac death02.03.04.016; 08.04.01.0080.001101%-
Anal haemorrhage07.12.03.004; 24.07.02.0290.000612%
Quadriparesis17.01.04.0120.000245%-
Urethral haemorrhage20.07.01.003; 24.07.03.0060.000734%-
Tumour haemorrhage16.32.03.008; 24.07.01.0280.000734%
Pituitary haemorrhage05.03.04.005; 17.08.01.019; 24.07.04.0090.000245%-
Bradyarrhythmia02.03.02.0150.000245%-
Shock haemorrhagic14.05.05.003; 24.06.02.0140.017738%-
Left ventricular hypertrophy02.04.02.0140.000367%-
Abnormal clotting factor01.01.02.0050.000538%-
Dry gangrene23.06.06.003; 24.04.03.0180.000367%-
Cardiac death02.03.04.015; 08.04.01.0070.000367%-
Lung cancer metastatic16.19.02.003; 22.08.01.0040.000734%-
Urogenital haemorrhage20.08.01.006; 21.10.05.008; 24.07.01.0440.001028%-
Spinal epidural haematoma12.01.13.006; 17.08.01.038; 24.07.04.0200.000245%-
Scleral haemorrhage06.07.01.002; 24.07.05.0090.000245%-
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 22 Pages